A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab

Chinese Academy of Medical Sciences & Peking Union Medical College

Status: Enrolling

Conditions: AL Amyloidosis

Study type: Observational

Funder types: Other

Identifiers

NCT05277493

AL amyloidosis registry

Details and patient eligibility

About

The purpose of this protocol is to generate a registry of Chinese patients with AL amyloidosis treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined with chemotherapy.

Enrollment: 500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years and older
• newly diagnosed or refractory/relapsed AL amyloidosis
• treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined with chemotherapy

Exclusion criteria

• co-diagnosis of multiple myeloma or Waldenström's macroglobulinemia